Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study
Introduction: We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors. Materials and methods: This was a single-center, open-label, phase I study with two consecutive cohorts (250 mg and 200 mg cohorts)...
Main Authors: | Shunsuke Kondo, Yuki Katsuya, Kan Yonemori, Keiko Komuro, Masatoshi Sugeno, Toshio Kawata, Dana Ghiorghiu, Didier Meulendijks, Noboru Yamamoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294224000212 |
Similar Items
-
Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
by: Yu-Ling Lu, et al.
Published: (2021-07-01) -
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
by: Pia Roering, et al.
Published: (2022-08-01) -
Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
by: Alexander Y. Deneka, et al.
Published: (2020-01-01) -
Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers [Retraction]
by: Yu G, et al.
Published: (2023-03-01) -
Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer
by: Yingshi Zhang, et al.
Published: (2023-01-01)